UA99628C2 - Бензолсульфонамидные соединения, пригодные для лечения расстройств, восприимчивых к модуляции дофаминового рецептора d3 - Google Patents

Бензолсульфонамидные соединения, пригодные для лечения расстройств, восприимчивых к модуляции дофаминового рецептора d3

Info

Publication number
UA99628C2
UA99628C2 UAA201003729A UAA201003729A UA99628C2 UA 99628 C2 UA99628 C2 UA 99628C2 UA A201003729 A UAA201003729 A UA A201003729A UA A201003729 A UAA201003729 A UA A201003729A UA 99628 C2 UA99628 C2 UA 99628C2
Authority
UA
Ukraine
Prior art keywords
alkyl
dopamine
fluorinated
respond
treating disorders
Prior art date
Application number
UAA201003729A
Other languages
English (en)
Ukrainian (uk)
Inventor
Шон Кольм ТЕРНЕР
Андреас ХАУПТ
Вільфрід Брайє
Удо ЛАНГЕ
Карла ДРЕШЕР
Ліліане УНГЕР
Ана Люсія Йонген-Рело
Антон Бєспалов
Original Assignee
Ебботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ебботт Гмбх Унд Ко. Кг filed Critical Ебботт Гмбх Унд Ко. Кг
Publication of UA99628C2 publication Critical patent/UA99628C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение касается соединений формулы EMBED ISISServer , (I) где R1 выбран из группы, состоящей из водорода, линейного С1-С3алкила и фторированного линейного С1-С3алкила; R2 представляет собой водород или метил; R3 выбран из групы, состоящей из водорода, галогена, С1-С2алкила, фторированного С1-С2алкила, С1-С2алкокси и фторированного С1-С2алкокси, R4 представляет собою С1-С2алкил или фторированный С1-С2алкил; n представляет собой 0, 1 или 2; и физиологически стойкие соли этих соединений и их N-оксиды. Изобретение также касается фармацевтической композиции, содержащей по меньшей мере одно соединение формулы (I) и/или по меньшей мере одну ее физиологически стойкую кислотно-аддитивную соль, и способа лечения заболеваний, восприимчивых к влиянию антагонистов дофаминового рецептора D3 или агонистов дофамина D3, включающего введение эффективного количества по меньшей мере одного соединения или физиологически стойкой кислотно-аддитивной соли формулы I субъекту, нуждающемуся в этом.
UAA201003729A 2007-10-31 2008-10-30 Бензолсульфонамидные соединения, пригодные для лечения расстройств, восприимчивых к модуляции дофаминового рецептора d3 UA99628C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119788 2007-10-31

Publications (1)

Publication Number Publication Date
UA99628C2 true UA99628C2 (ru) 2012-09-10

Family

ID=40280677

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201003729A UA99628C2 (ru) 2007-10-31 2008-10-30 Бензолсульфонамидные соединения, пригодные для лечения расстройств, восприимчивых к модуляции дофаминового рецептора d3

Country Status (24)

Country Link
US (4) US20100210664A1 (ru)
EP (1) EP2203426B9 (ru)
JP (1) JP5680416B2 (ru)
KR (1) KR20100080500A (ru)
CN (1) CN101687802B (ru)
AT (1) ATE522505T1 (ru)
AU (1) AU2008320875B2 (ru)
BR (1) BRPI0812978A2 (ru)
CA (1) CA2690976A1 (ru)
CO (1) CO6251289A2 (ru)
CR (1) CR11188A (ru)
DO (1) DOP2009000295A (ru)
EC (1) ECSP099832A (ru)
ES (1) ES2371308T3 (ru)
GT (1) GT200900332A (ru)
IL (1) IL202814A (ru)
MX (1) MX2009014236A (ru)
MY (1) MY153300A (ru)
NZ (1) NZ582095A (ru)
RU (1) RU2485103C2 (ru)
TW (1) TWI469782B (ru)
UA (1) UA99628C2 (ru)
WO (1) WO2009056600A1 (ru)
ZA (1) ZA200909171B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916653C (en) 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds

Also Published As

Publication number Publication date
ATE522505T1 (de) 2011-09-15
CO6251289A2 (es) 2011-02-21
GT200900332A (es) 2012-04-03
JP2011500771A (ja) 2011-01-06
AU2008320875B2 (en) 2013-08-01
EP2203426A1 (en) 2010-07-07
TWI469782B (zh) 2015-01-21
CA2690976A1 (en) 2009-05-07
RU2010121830A (ru) 2011-12-10
TW200932234A (en) 2009-08-01
WO2009056600A1 (en) 2009-05-07
CN101687802B (zh) 2014-02-26
ES2371308T3 (es) 2011-12-29
MY153300A (en) 2015-01-29
ECSP099832A (es) 2010-01-29
CR11188A (es) 2010-05-27
US20100210664A1 (en) 2010-08-19
ZA200909171B (en) 2012-05-30
DOP2009000295A (es) 2010-01-31
IL202814A (en) 2015-05-31
EP2203426B9 (en) 2013-02-13
AU2008320875A1 (en) 2009-05-07
US20150175570A1 (en) 2015-06-25
JP5680416B2 (ja) 2015-03-04
NZ582095A (en) 2012-08-31
CN101687802A (zh) 2010-03-31
US20110319421A1 (en) 2011-12-29
EP2203426B1 (en) 2011-08-31
KR20100080500A (ko) 2010-07-08
MX2009014236A (es) 2010-05-03
RU2485103C2 (ru) 2013-06-20
BRPI0812978A2 (pt) 2014-12-16
IL202814A0 (en) 2010-06-30
US20140200224A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
TW200726739A (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007092364A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2006057922A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
PH12013500848A1 (en) Trpv1 antagonists and uses thereof
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
WO2007120575A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
UA99361C2 (ru) ТРИАЗИНЫ КАК ИНГИБИТОРЫ PI3-КИНАЗЫ I mtor
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
WO2007075749A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
CY1116190T1 (el) Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
MX2009010731A (es) Derivados de acido 1-(1-bencilpiperidin-4-il)benzimidazol-5-carbox ilico para el tratamiento de diabetes mellitus.
TW200633710A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
UA99634C2 (ru) Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
MY153733A (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
UA99628C2 (ru) Бензолсульфонамидные соединения, пригодные для лечения расстройств, восприимчивых к модуляции дофаминового рецептора d3
TW200510395A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor